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Quality of Life in Cushing’s disease: A long term issue?
La qualité de vie dans la maladie de Cushing : une affaire à long terme ?
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bstract
The purpose of this review is to describe how quality of life (QoL) is impaired in patients with hypercortisolism due to Cushing’s syndrome
f any aetiology, including pituitary-dependent Cushing’s disease. It is worse in active disease, but improvement after successful therapy is often
ncomplete, due to persistent physical and psychological co-morbidities, even years after endocrine “cure”. Physical symptoms like extreme
atigability, central obesity with limb atrophy, hypertension, fractures, and different skin abnormalities severely impair the affected patients’
veryday life. Psychological and cognitive problems like bad memory, difficulties to concentrate and emotional distress, often associated with
nxiety and depression, make it difficult for many patients to overcome the aftermath of treated Cushing’s syndrome. Recent studies have shown
iffuse structural abnormalities in the central nervous system during active hypercortisolism, thought to be related to the wide distribution of
lucocorticoid receptors throughout the brain. Even though they improve after treatment, normalization is often not complete. Shortening the
xposure to active Cushing’s syndrome by reducing the often long delay to diagnosis and promptly receiving effective treatment is highly desirable,
ogether with preparing the patient for the difficult periods, especially after surgery. In this way they are prepared for the impairments they perceive
n every day life, and live with the hope of later improvement, which can be therapeutic in many instances.
 2018 Elsevier Masson SAS. All rights reserved.
eywords: Cushing’s syndrome; Quality-of-life impairment; Persistent co-morbidities; Anxiety; Depression; Coping
ésumé
L’objectif de cette revue est de décrire l’altération de la qualité de la vie en cas d’hypercorticisme induit par la maladie de Cushing, toutes étiologies
onfondues, y compris le Cushing hypophysaire. Cette altération est maximale en phase active de la maladie, mais l’amélioration apportée par le
raitement n’est souvent que partielle, à cause des comorbidités physiques et psychologiques résiduelles, même des années après la « guérison »
ndocrinologique. Des symptômes physiques tels qu’une fatigabilité extrême, uneobésité centrale avec atrophie musculaire des membres, une
ypertension artérielle, des fractures et diverses anomalies cutanées diminuent la qualité de vie quotidienne. Des problèmes psychologiques et
ognitifs, tels la perte de mémoire, des difficultés de concentration et la souffrance émotionnelle, souvent associés à l’anxiété et la dépression,
mpêchent souvent les patients de vaincre les séquelles d’une maladie de Cushing pourtant guérie. Des études récentes rendent compte d’anomalies
’hypercorticisme actif, qui seraient dues à la large répartition cérébrale destructurelles diffuses au niveau du système nerveux central en cas de d
écepteurs glucocorticoïdes. Ces anomalies sont améliorées par la thérapie, mais le retour au normal est souvent incomplet. Il est donc fortement
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ouhaitable que la durée d’exposition à la maladie de Cushing active soit réduite, en réduisant le délai diagnostique, qui est souvent long, et en
nitiant rapidement un traitement adapté, tout en préparant le patient à faire face aux périodes difficiles, notamment au décours de la chirurgie.
insi, le patient peut se préparer à une certaine baisse de la qualité de la vie de tous les jours, mais vivre dans l’espoir d’une amélioration ultérieure,
spoir qui est souvent lui-même de valeur thérapeutique.
 2018 Elsevier Masson SAS. Tous droits réservés.
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Table 1
Psychological phases of adaptation.
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.  Introduction
Hypercortisolism, characteristic of active Cushing’s syn-
rome (CS) determines a host of invalidating signs and
ymptoms, which negatively impact on patients’ health-related
uality of life (QoL). These include physical problems like
eight gain leading to central obesity, muscle weakness
nd fatigability, bone fractures, hypertension, skin abnormal-
ties (thinning, easy bruising, red striae, ulcerations) as well
s psychological impairment (bad memory, emotional dis-
ress, anxiety, depression, etc). Even though surgery with or
ithout additional medical therapy can lead to control of
ypercortisolism, often signs and symptoms typical of active
ypercortisolism do not revert completely; this is so in Cushing’s
yndrome (CS) of any aetiology (adrenal, pituitary-dependent
ushing’s diseases – CD−, or ectopic ACTH secretion), and
etermines persistent impairment of QoL, despite being consid-
red endocrinologically “cured” [1].
This prior chronic exposure to endogenous glucocorticoid
GC) excess in CS is also associated with greater morbidity
nd mortality, related to complications such as components
f the metabolic syndrome, cardiovascular events, muscle
eakness, bone fractures, neurocognitive impairment and psy-
hiatric disorders [2]. Thus, after resolution of hypercortisolism,
atients still often complain of physical and psychological
mpairment [3], including cognitive changes, depression, less
elf-confidence and altered illness perception. All this deter-
ines a slow and incomplete recovery, severely affecting QoL
ven long-term after control of cortisol excess [1]. This is a mat-
er of concern for many patients and their partners [4–6] and
 challenge for clinicians. To further improve their outcome,
atient-reported outcome measures are worth considering, as
ell as self-management programmes to enhance self-efficacy,
s recently shown in a clinical trial [7].
Early detection of hypercortisolism to reduce the delay to
iagnosis, and effective treatment aimed at achieving persistent
emission is mandatory in CS patients to improve long-term
rognosis and QoL [1]. Life-long evaluation with periodic
aboratory and clinical assessment, is also highly recommend-
ble even long-term after remission, to appropriately manage
omorbidities (diabetes, hypertension, dyslipidemia) according
o current guidelines.. The  concept  of  health-related  quality  of  life  (QoL)
QoL is a patient-reported outcome measure, which can




th phase: sadness, which leads to either depression, or adaptation (the
latter is easier if you are positive!)
uestionnaires. It reflects the individual patient’s definition of
ellbeing, including perceptions of physical, psychological,
motional and social health issues. Disease–generated ques-
ionnaires tend to be more sensitive in identifying limitations
pecific of the disease, as well as changes after treatment, but
annot be used in normal subjects or in other diseases, while
eneric questionnaires are useful in any population, and allow
omparing QoL in different diseases or with normal subjects.
Domain-specific” questionnaires are designed to evaluate a
etermined problem, for example, fatigability, pain, dyspnoea
r sexual dysfunction, and are therefore useful to compare the
egree of impairment of a specific domain [1].
Thus, after psychometric validation and translation into the
anguages of the patient populations to be investigated, QoL
cores can be used to highlight the patient’s impression on
linical aspects often not approached clinically, despite being
mportant for everyday life [8], and complement the biochemical
nd radiological tests routinely used in patient’s follow-up.
. Effect  o chronic  hypercortisolism  on  health-related
uality of  life
With the availability of two different Cushing-specific QoL
uestionnaires (CushingQoL [9] and Tuebingen CD-25 [10,11]),
ew knowledge on impairment suffered by CS patients has
merged. CushingQoL consists of 12 questions with a five option
ikert scale answer, which was described as unidimensional
12]. Recently, however, two subscales (psychosocial issues
nd physical problems) were identified and showed adequate
odel fit. Data were obtained from patients in remission from
S (n  = 341) recruited from the Cushing’s Syndrome Research
oundation’s email lists; they completed the CushingQoL ques-
ionnaire and a short demographics survey [13]. Regardless of
he scoring solution used, it was concluded that CushingQoL
ad proven to be a valuable resource for assessing health-related
oL in patients with CS (Table 1).
The Tuebingen CD quality of life inventory (Tuebingen CD-
5) [10,11] is a 25-item questionnaire covering six essential
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omains of HRQoL. It has showed improvement after success-
ul surgery in 17 CD patients [14]; three quarters of the patients
ad impaired QoL preoperatively, but only one third after suc-
essful surgery. A better postoperative QoL was observed in
he presence of less comorbidities (≤2) and greater morning
ortisol decrease. Predictors for postoperative improvement in
oL were greater preoperative QoL impairment and a younger
ge, as also reported using the CushingQoL questionnaire [15].
ther predictors of impaired QoL are having experienced a long
elay until a correct diagnosis of CS was obtained [16] or hav-
ng seen more physicians before a correct diagnosis of CS was
ade [5,17]. Whether this means that patients who experience
reater discomfort demand more physician visits, or it simply
ndicates a longer duration of symptoms, is not yet clear. In com-
arison, patients who are treated by physicians who specialize
n CS report better QoL. Since a bad QoL can influence working
apacity, it may have major economic consequences for patients
nd their families [5,17].
Similar results with the SF-36 and Tuebingen CD-25 ques-
ionnaires were also reported after bilateral adrenalectomy in 50
atients with CS, most of which were followed for a median of
1 years [18]. While comorbidities like hypertension, diabetes
ellitus, osteoporosis, muscle weakness, cushingoid phenotype
nd menstrual irregularity improved after surgery, QoL was still
mpaired in 45% of female and 16.7% of male patients, when
ompared with a healthy population [18].
.1. Physical  limitations  in  Cushing’s  syndrome
Endogenous (of adrenal, pituitary or ectopic origin) or exoge-
ous CS (due to treatment with GC) is associated with persistent
hysical morbidity (including increased cardiovascular risk,
atigability, myopathy and bone fragility) which negatively
mpact on well-being and QoL. This QoL impairment has been
hown with both generic and dimension-specific questionnaires
i.e., SF-36 survey, the Hospital Anxiety and Depression Scale
HADS)), and disease-specific questionnaires, like the Cush-
ngQoL [19–21] and the Tuebingen CD-25 questionnaires [14].
The characteristic physical complaints of active CS impair
oL. Data from the European Cushing syndrome registry
RCUSYN show that weight gain is reported in over 80% of
atients, hypertension, skin alterations and myopathy in at least
wo thirds, and other complaints in descending order of fre-
uency are hirsutism, menstrual irregularities, reduced libido,
iabetes mellitus and fractures (the latter observed in at least
0% of the patients). The negative impact on QoL was further
ncreased by the delay to diagnosis of a median of two years
interquartile range: three years) in the overall series [15]. And
ven after surgery, the time to see an improvement in symptoms
nd signs like hypertension, menstrual irregularity, moon face
nd plethora, central obesity, purple striae or easy bruising is
ver 6 months on average, and 9 to 12 months for buffalo hump,
irsutism, diabetes and muscle weakness [22].Although obesity is a characteristic of CS, differences in
oL were identified between both diseases, using the SF-36 sur-
ey and a symptom questionnaire [23]. Obese patients, mostly
omen with a mean average age between 40 and 50 years, had
4
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etter QoL in the mean physical component summary (PCS)
core, but worse mean mental component summary (MCS) than
S patients. The presence of more CS symptoms worsened the
CS and MCS scores, while obese patients surprisingly showed
orse mental health scores than the CS population. BMI corre-
ated with PCS in obesity, but not in CS, and was not associated
ith MCS in either group.
A large study of 123 patients with CS of both pituitary and
drenal origin in remission for a mean of 13.3 + 10.4 years,
howed worse QoL on practically all dimensions investigated,
ompared to a matched control group. If patients were in remis-
ion after pituitary surgery without hormonal deficiencies, QoL
as impaired in only 50% of the dimensions evaluated. A
horter duration of remission and women (compared to men)
ad a negative impact on QoL, and it remained impaired despite
ong-term remission of CS, independently of aetiology (i.e., pitu-
tary, adrenal, or ectopic ACTH secretion), the presence or not
f hormonal deficiencies and treatment strategies, pointing to
ypercortisolism as the cause of these persistent problems, rather
han the location of the originating tumour [17,24].
.2. Psychological  consequences  of  Cushing’s  syndrome
Hypercortisolism exerts irreversible toxicity on brain struc-
ures and determines sustained psychological dysfunction and
tructural brain abnormalities, including atrophy of different
tructures, even after remission of hypercortisolism [25,26].
hese brain volume decreases are especially seen in active
ypercortisolism and in patients diagnosed at an older age, which
s thought to be related to less brain plasticity compared to
ounger subjects; other factors like longer disease duration and
onger exposure to hypercortisolism also are related to worse
sychological outcome [25–27] (Fig. 1).
Using the Beck Depression Inventory II (BDI-II), the SF-
6 and the multidimensional body-self relations questionnaire
MBSRQ), QoL in the general health category and perception of
ody image were worse in 40 patients with CD who underwent
ranssphenoidal surgery, compared to 40 healthy controls [28].
n contrast with several other studies, however, no differences
n depression scores were found between CD patients globally
nd controls. But in CD patients without remission, depression
as more prevalent than in both CD patients with remission
nd healthy subjects. Additionally, physical functioning, bodily
ain and general health scores of the SF-36 questionnaire in CD
atients without remission were also worse than in CD patients
n remission and healthy subjects.
A higher prevalence of “maladaptive” personality traits in
S patients even after long-term cure, may affect their everyday
oL [29]. They appear to perceive that they are characterized by
unpleasant” increased-anxiety traits (pessimism, neuroticism,
hyness with strangers and low extraversion), and try to answer
n a rather “pleasant” (or socially desirable) way.. Changes  in  QoL  over  time  in  CS
Even though after successful treatment some improvement is
sually perceived, it often takes months or over a year, so that the
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Fig. 1. Structural brain abnormalities and neuropsy
mmediate postoperative phase can be very challenging due to a
glucocorticoid deprivation phase”, characterised by more pain,
evere fatigability, worries about physical appearance, troubles
ith their family life and partner relations, decreased work or
chool performance, helplessness often leading to depression
nd a bad perception of QoL [5]. Additionally, attempting to
nd the lowest glucocorticoid substitution dose possible to main-
ain a satisfactory well-being after successful surgery (leading
o adrenal axis inhibition), and favour endogenous recovery of
he adrenal axis inhibition, may be difficult.
Predictors for worse QoL in CS include a long delay to diag-
osis of CS [30], requiring more physicians before a correct
iagnosis [31,32], and presence of ‘maladaptive’ personality
raits like pessimism, neuroticism, shyness with strangers and
ow extraversion [33]. In contrast, a worse baseline QoL score,
 younger age, and being treated by specialists knowledgeable
n CS predict a greater postoperative improvement in QoL [34].
Making the patients aware of the psychological and physi-
al consequences of successful treatment and therefore being
cured” helps to understand this difficult period for the patients.
t is important to prepare the patient so he/she is aware and can try
o cope with the aftermath, a first step to facilitate improvement
n the long term, since they tend to experience persistently nega-
ive illness perceptions. Most patients don’t feel much better
fter treatment, and some even feel worse; this is most fre-
uently related to sustained fatigue, decreased muscle strength
nd weakness, weight gain especially around the abdomen,
orgetfulness, trouble sleeping, depression, anxiety, and poor
sychosocial functioning [5], consistent with long-lasting neg-
tive effects of previous hypercortisolism on cognitive function
nd behaviour [17,18]. All this negatively influences QoL, even
fter more than 10 years of remission [35,36]. Additionally,
uration of adrenal insufficiency and hydrocortisone usage are





ic disorders described in Cushing’s syndrome [25].
Another longitudinal study in 17 patients with active hyper-
ortisolism, investigated the effect of sequential stepwise
edical therapy on QoL and recovery of physiological sali-
ary and plasma cortisol diurnal rhythm [37]. Treatment with
he somatostatin analogue pasireotide was followed by the
opamine agonist cabergoline, and later the adrenal-blocking
gent ketoconazole if normal urinary free cortisol (UFC) was not
eached. The CushingQoL, Nottingham Health Profile (NHP),
ADS, Multidimensional Fatigue Inventory (MFI) and RAND-
6 instruments were evaluated. RAND-36 includes the same set
f items as SF-36, and were both developed in the Medical Out-
omes Study, but scoring of general health and pain scales differ
38]. After 80 days, 88% (15/17) of the patients normalized
FC. Patients then either continued medical therapy for 1 year
r underwent surgery. Cortisol diurnal rhythm was preserved at
aseline in 5/17 patients; in another 6/12 with disturbed baseline
hythm, recovery occurred, but not correlated with QoL, which
as impaired in most subscales (18/20) in CD patients compared
o literature-derived controls. After 80 days, patients reported
ore pain (interpreted as a reflection of steroid-withdrawal),
ut QoL did not improve or deteriorate. Baseline CushingQoL
cores (around 50) tended to improve after 1 year of remission in
 patients that continued medical therapy (to over 75), reflect-
ng how long it takes for QoL to recover, despite control of
ypercortisolism.
A phase III, randomized, double-blind study assessed the
elationships between QoL and UFC and CD-related signs
nd symptoms in patients with elevated UFC receiving s.c.
asireotide 600 or 900 mg twice daily for 12 months [21,39].
aseline QoL using CushingQoL, clinical signs and features
f CD and depression (evaluated with the Beck Depression
nventory II (BDI-II)) were compared to follow-up evaluation.
hanges in CushingQoL and the proportion of patients achiev-
ng a clinically meaningful improvement in CushingQoL were
lso compared among patients stratified by mean UFC con-
ARTICLE IN PRESS+ModelANDO-1014; No. of Pages 6
S.M. Webb et al. / Annales d’Endocrinologie xxx (2017) xxx–xxx 5
Table 2
The example of psychological adaptation in Cushing’s syndrome.
Prior to diagnosis




New anxieties and needs: expert professionals; access to these
professionals, to required tests & to therapies; reliable information
(therapies, legal issues, etc.); support beyond endocrine care
(confront QoL issues)
Confront the situation of living with Cushing’s Syndrome
Understanding by the family and your environment is important








































Significant improvements obtained with a nursing educational program on Cush-
ing’s syndrome patients compared to control patients followed routinely [41].
Greater physical activity
Better adherence to therapy
Quantitative and qualitative improvement in sleep patterns
Less pain
Reduction of health costs
Number of smoked cigarettes



























ing’s syndrome. Pituitary 2012;15:319–29.A message of hope!
rol status (controlled, partially controlled, and uncontrolled)
t month 6. Analyses were also conducted at month 12, with
ultivariable adjustment. Change in CushingQoL was corre-
ated with changes in mean UFC, BMI, weight, and BDI-II at
onth 12, but not at month 6. CushingQoL scores at month
2 were better for controlled and partially controlled patients
han for uncontrolled patients with persistently elevated UFC.
his led to conclude that among patients achieving biochemi-
al control with daily s.c pasireotide treatment, improvement of
oL was observed at 12 months, especially in patients reaching
iochemical control [39]. The minimal important difference in
ushingQoL score to be clinically meaningful was found to be
0.1, based on the half-standard deviation distribution method
21] as recommended by the FDA and other regulatory agen-
ies in the USA and Europe, allowing comparison of different
reatments on the patient’s outcome. This longitudinal study con-
rmed CushingQoL as a reliable, valid, and responsive (good
est-retest reliability and sensitivity to change) questionnaire to
ssess QoL and other relevant clinical outcomes in adults with
D (Table 2).
. How  can  patients  attempt  to  improve  QoL  after  being
iagnosed with  CS
Even in the long-term management of CS, being aware of
he changing physical and psychological situations does help
atients conform, with the hope of final improvement [40]. One
hould be aware that common complaints like cognitive impair-
ents and psychiatric disorders, as well as periodic follow-ups
o evaluate pituitary function and detect possible recurrences
f hypercortisolism, all put extra stress on these CS patients,
hich in turn worsens psychological issues and often leads to
 bad QoL. Encouraging the patients to take care of themselves
an help them feel better and improve their QoL, with the sup-
ort of friends and family, so they can feel they are taking the
eins of their lives again. Things to recommend are to consider
aking up new hobbies or challenges within their capacities, as
ell as following healthy diets and regular exercise and taking
heir prescribed treatment as indicated [31]. It is worth trans-
itting a message of hope, in the sense that despite the manyimprovement
hanges after CS, it is still possible to be happy if one works at
t [17].
A specific nursing educational program, addressed to CS
atients has been shown to exert a positive effect on different
iving habits and in parallel, improved QoL. They improved their
hysical activity, healthy lifestyle habits, adherence to therapy,
leep patterns and experienced a reduction in pain level and in
he use of health resources, all influencing QoL positively. Those
atients who improved most with this educational intervention
ere those with greatest impairment in their QoL [41], while if
he patient was depressed, recovery of QoL was more difficult
Table 3).
. Conclusions
Over the last decade it has become evident that QoL is
everely affected in patients diagnosed with Cushing’ syn-
rome, and may not normalize despite successful treatment
nd endocrine “cure”. The reasons are multifactorial, including
hysical symptoms (including fatigability, abnormal body image
ue to central obesity and several skin problems, hypertension,
tc) and psychological complaints; additionally, morpholog-
cal abnormalities in the central nervous system, reflect the
lucocorticoid toxicity on the brain, presumably through the
lucocorticoid receptors identified in different brain areas.
Understanding and encouragement by the health care
roviders, and in some cases psychological support can help
atients through this difficult period with the hope of ultimate
mprovement.
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